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To test the hypothesis that tricyclic antidepressant use increases invasive female breast cancer incidence, we carried out a
case–control study within the population of female beneﬁciaries of the Saskatchewan Prescription Drug Plan aged 535 years
from 1981–1995 with no history of cancer since 1970. This agency has provided full or partial coverage for outpatient
prescriptions to Saskatchewan residents since 1975. We accrued 5882 histologically proven cases and 23517 controls,
randomly selected from the source population and individually matched on age and sampling time. Heavy exposure to any
tricyclic antidepressants was associated with an elevated rate ratio for breast cancer 11–15 years later (2.02, 95% conﬁdence
interval: 1.34–3.04). Post hoc analyses based on the results of genotoxicity studies carried out using Drosophila melanogaster
suggested that the increased risk could be attributed to the use of the six genotoxic tricyclic antidepressants, and not to the
use of the four nongenotoxic tricyclic antidepressants. However, our results may have been confounded by the effects of
other determinants of breast cancer associated with tricyclic antidepressant use.
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Concerns about the safety of tricyclic antidepressants (TCAs)
(Marx, 1992; Miller, 1993; Steingart and Cotterchio, 1995), brought
about by the results of animal experiments designed to identify
potential carcinogens, raise the issue of whether TCAs are involved
in the development of breast cancer.
To study the effects of TCA use on breast cancer risk, we carried
out a population-based case–control study, using data obtained
from the records of the Saskatchewan Cancer Agency (Canada)
and the Saskatchewan Prescription Drug Plan, which has provided
outpatient drug coverage to the Saskatchewan population since
1975.
SUBJECTS AND METHODS
Study populations
The source population consisted of the women aged 535 years,
eligible to beneﬁt from the Saskatchewan Prescription Drug Plan
during 1981 to mid-1995, with no history of cancer since 1970
other than non-melanoma skin cancer or carcinoma in situ of
the cervix. From this population we selected cases of histologically
proven invasive female breast cancer and controls (4/case),
matched on age and sampling date. Further details can be found
elsewhere (Sharpe et al, 2000).
To be in our study, subjects must have been eligible to beneﬁt
from the Saskatchewan Prescription Drug Plan for 5ﬁve years
before the date of diagnosis of the cases or the sampling date of
the controls; hereafter, both dates will be designated as the ‘index
date’. This ensured that sufﬁciently long records of their drug use,
if any, would be available for analysis.
Databases and linkage methods
Information in the databases of the Saskatchewan Prescription
Drug Plan and the Saskatchewan Cancer Agency was linked elec-
tronically using subjects’ unique personal health care
identiﬁcation numbers; see Rawson et al (1992).
Drug exposure data
Exposure data were obtained from the Saskatchewan Prescription
DrugPlandatabase fortheperiod between theindex dataandJanuary
1, 1976 or the date upon which a subject ﬁrst became eligible to bene-
ﬁt from the Saskatchewan Prescription Drug Plan, whichever was
later. The records of exposure, if any, ranged from 5–19.5 years in
length. Because of the small numbers with information available for
years 16–19.5, we did not use the information collected then.
The following data were extracted for each antidepressant out-
patient prescription: the dispensing date, the class and drug identity
according to the American Hospital Formulary System, the number
ofpillsdispensed,andthestrength(mg/pill).Thedailydoseandtreat-
ment duration pertaining to each prescription were not available.
No data were available from 1 July 1987 to December 31, 1988,
because at that time the Saskatchewan Prescription Drug Plan did
not record most drug dispensing to individuals (Rawson et al,
1992). The database also lacked information on drugs dispensed
in hospitals and as samples, as well as drugs dispensed before being
listed in the Saskatchewan Formulary and drugs covered under the
Exception Drug Program, unless the physician applied for coverage
and it was approved.
Ethical issues and conﬁdentiality
Extraction of data from the electronic databases of the Saskatche-
wan Cancer Agency and the Saskatchewan Prescription Drug
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Statistical analysis
We analyzed exposure to TCAs either as a single class of drugs or
as two separate classes based on their chemical structures.
To study the effects of exposure timing we a priori divided time
preceding the index date into ﬁve periods: months 1–6, months
7–12, years 2–5, years 6–10, and years 11–15. Exposure during
each was characterized with the average rate of dispensing TCAs,
which was based on the average number of moles of each different
TCA dispensed during each period (mi=average moles day
71
dispensed for TCAi during a given period). The sum of the
averages, i.e. Smi for all the TCAs dispensed during a given period,
represented the measure of exposure. The number of moles
dispensed for each drug was calculated from the molecular weight
given in the Merck Index (Budavari et al, 1989: see Table 1).
We estimated the duration of drug use during the different periods
of time by dividing them into 3-month intervals (91 days) and count-
ing the number during which a prescription was dispensed; e.g., drug
use during 11 of 20 intervals was 55% of the time. We could not esti-
mate the overall duration of use, because no drug dispensing data
were available prior to 1976, from July 1, 1987 to December 31,
1988, and for immigrants to Saskatchewan prior to their becoming
eligible to receive beneﬁts from the Prescription Drug Plan.
If the drug exposure history for a period was missing or incom-
plete due to the reasons listed above, the subject was assigned to a
separate exposure category designated ‘other’ (Huberman and
Langholz, 1999).
Details of the statistical methods used can be found elsewhere
(Sharpe et al, 2000). We followed Miettinen’s view that exposures
during ‘different time periods represent separate determinants ...
mutually confounded, and thus requiring joint representation in
the same model’ (Miettinen, 1985).
RESULTS
We accrued 5882 cases and 23517 controls. The mean age of the
cases at diagnosis was 64.1 years (13.3 s.d.). Some 18.7% of the
cases and 18.6% of the controls had received a prescription for a
TCA.
The ‘crude’ and ‘adjusted’ analyses in Table 2 show the rate ratios
(RRs) for breast cancer associated with any TCA exposure during
each period without and with control for any TCA exposure during
the other periods, respectively. The adjusted model shows that only
TCA exposure during years 11–15 was associated with a signiﬁ-
cantly increased risk of breast cancer: among the highly exposed
(Smi415 moles610
75 day
71) the incidence was twice that of
the unexposed (RR=2.02, 95% CI: 1.34–3.04).
Similar analyses were carried out with exposure expressed as the
duration of any TCA use during each period. The overall pattern of
results was similar. For TCA use 71–100% of the time during
years 11–15, the adjusted RR was 1.52 (95% CI: 1.03–2.26).
The 410 year delay between TCA exposure and the increase in
the RR for breast cancer suggested to us that the drugs might be
acting as tumour initiators rather than as tumour promoters.
Therefore, we searched the literature for evidence of genotoxicity
associated with TCA use.
Van Schaik and Graf (1991, 1993) evaluated TCAs using a geno-
toxicity assay involving wing development in Drosophila
melanogaster aimed at identifying potential carcinogens. They
found that amitriptyline, maprotiline, nortriptyline, and protripty-
line were not genotoxic, whereas clomipramine, desipramine, and
imipramine clearly were. Since the former four compounds have
a carbon atom at position ﬁve in the six- or seven-membered
central ring, and the latter three have a nitrogen at that position
in the seven-membered central ring, they hypothesized that the
nitrogen atom in the seven-membered central ring was responsible
for the genotoxicity. Recently, Graf (personal communication)
evaluated the genotoxicity of amoxapine, doxepin, and trimipra-
mine using the same assay. As expected on the basis of the
structural hypothesis, trimipramine was genotoxic. Although doxe-
pin has a carbon at position ﬁve, its structure is atypical in that an
oxygen atom occupies position eleven in the central ring (Budavari
et al, 1989); it was also genotoxic. Several aspects of the structure
of amoxapine are atypical (Budavari et al, 1989); the central ring
includes both a nitrogen and an oxygen atom – it too was geno-
toxic.
Accordingly, we decided to test the hypothesis that the use of
genotoxic TCAs was associated with an increased risk of breast
cancer.
We deﬁned exposure in terms of Smi for the two classes of TCAs,
based on their genotoxicity in Drosophila: the nongenotoxic TCAs
(amitriptyline, maprotiline, nortriptyline, and protriptyline), and
the genotoxic TCAs (amoxapine, clomipramine, desipramine, doxe-
pin, imipramine, and trimipramine). Since some subjects used drugs
from both classes, we included variables representing exposure to
each class in a single logistic model to control possible confounding
of the effects of one drug class by the other. Table 3 (left panel) shows
that exposure to the nongenotoxic TCAs was not associated with any
increased risk. However, increasing exposure to the genotoxic TCAs
was associated with a trend towards an increasing RR 11–15 years
later (P-trend=0.0009; right panel, Table 3). At the highest exposure
level the RR was 2.47 (95% CI: 1.38–4.40).
We also carried out an analysis in which potential confounding
between the two drug classes was controlled by restriction. Expo-
sure was deﬁned during each period using mutually exclusive
categories: exclusive use of TCAs from each class, as well as expo-
sure to both classes. Since there was a common referent for each
period consisting of subjects with no exposure to any TCA, the
ratio of the RRs associated with exclusive exposure to each class
provided an estimate of the ratio of the incidence of breast cancer
among subjects exposed to one class of TCAs to the incidence
among subjects exposed to the other. At the highest exposure level
the incidence associated with exclusive exposure to the genotoxic
TCAs during years 11–15 was 2.3 times greater than the incidence
associated with exclusive exposure to the nongenotoxic TCAs. The
RRs used in this calculation were 1.92 (95% CI: 0.93–3.95) and
0.84 (95% CI: 0.36–1.93), respectively.
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Table 1 Tricyclic antidepressants dispensed to cases (n=5882) and con-
trols (n=23 517) between the date on which each subject ﬁrst became
eligible to receive beneﬁts from the Saskatchewan Prescription Drug Plan
and her index date
Tricyclic
antidepressants
Molecular
weight
Total number
of prescriptions
dispensed
to cases
Total number
of prescriptions
dispensed
to controls
Amitriptyline 277.39 10 973 38 935
Amoxapine 313.79 257 1222
Clomipramine 314.87 1050 3683
Desipramine 266.37 678 1834
Doxepin 279.37 4113 13 508
Imipramine 280.40 2341 6878
Maprotiline 277.41 666 3062
Nortriptyline 263.37 182 556
Protriptyline 263.37 287 367
Trimipramine 294.42 5214 17 806
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ã 2002 The Cancer Research Campaign British Journal of Cancer (2002) 86(1), 92–97We also carried out an analysis like that of Table 3 in which
exposure was expressed as the estimated duration of use during
each period; see Table 4. There was no increased risk associated
with use of the nongenotoxic TCAs, but for the genotoxic TCAs
there was a trend towards an increasing RR with increasing dura-
tion of use during years 11–15 (P-trend=0.003). For drug use 71–
100% of the time during that period the RR was 2.39 (95% CI:
1.30–4.39). The corresponding analysis using restriction to control
confounding showed that at the highest exposure level the inci-
dence associated with exclusive exposure to the genotoxic TCAs
during years 11–15 was 2.4 times greater than the incidence asso-
ciated with exclusive exposure to the nongenotoxic TCAs. The RRs
used in this calculation were 1.90 (95% CI: 0.93–3.90) and 0.80
(95% CI: 0.40–1.61), respectively.
DISCUSSION
We found that increasing exposure to any TCAs during years 11–
15 was associated with a trend towards an increasing RR for breast
cancer (Table 2). Post hoc analyses based on classifying the drugs
according to their genotoxicity in Drosophila suggest that the use
of genotoxic TCAs was responsible for the increased risk (amoxa-
pine, clomipramine, desipramine, doxepin, imipramine,
trimipramine), while the use of the nongenotoxic TCAs was not
associated with an increased risk (amitriptyline, maprotiline,
nortriptyline, protriptyline).
Because our accrual of cases from the source population was
nearly complete (Parkin et al, 1997) and our exposure data were
collected routinely before the index date, there was little potential
for selection and recall bias concerning exposure.
Since our measures of exposure were based on outpatient prescrip-
tions, actual consumption of TCAs probably differed from our
estimates. It is unlikely that all drugs dispensed were ingested. If we
overestimated exposure, then the slope of the dose-risk relationship
that we observed would be less than the true slope (MacMahon
and Trichopoulos, 1996). Although we may have underestimated
exposure, since we had no information about some of the TCAs
dispensed (see Subjects and Methods), these amounts were probably
small relative to the amounts used in calculating exposure.
Could our results be confounded by the effects of other determi-
nants of breast cancer associated with TCA use?
Although depression was once considered to be associated with
the development of cancer as the result of immunologic and endo-
crine dysfunction, there is now little supporting evidence (Linkins
and Comstock, 1990; Spiegel, 1996). Although Penninx et al (1998)
recently found that the incidence of cancer was 1.9 times greater
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Table 2 RRs for breast cancer according to TCA exposure by time period before diagnosis
TCA exposure
Average daily dose
a Cases Controls
Crude Adjusted
Period before diagnosis (moles610
75 day
71) n=5882 n=23517 RR
b 95% CI RR
c 95% CI
1–6 months 0 4756 19 123 1.00 Referrent 1.00 Referrent
05Smi45 118 405 1.17 0.95–1.44 1.15 0.92–1.44
55Smi415 112 449 1.00 0.81–1.24 0.96 0.74–1.25
Smi415 113 410 1.11 0.90–1.37 0.84 0.59–1.19
P (trend) 0.30 0.31
Other
d 783 3130 – – – –
7–12 months 0 4727 19 024 1.00 Referrent 1.00 Referrent
05Smi45 114 388 1.18 0.96–1.47 1.16 0.92–1.47
55Smi415 103 446 0.93 0.75–1.15 0.92 0.70–1.21
Smi415 126 414 1.23 1.00–1.50 1.27 0.89–1.81
P (trend) 0.10 0.50
Other
d 812 3245 – – – –
2–5 years 0 2860 11 423 1.00 Referrent 1.00 Referrent
05Smi45 299 1284 0.93 0.81–1.06 0.91 0.80–1.05
55Smi415 89 301 1.18 0.93–1.50 1.15 0.89–1.50
Smi415 59 217 1.09 0.81–1.46 0.96 0.69–1.34
P (trend) 0.17 0.61
Other
d 2575 10 292 – – – –
6–10 years 0 2294 9238 1.00 Referrent 1.00 Referrent
05Smi45 287 1186 0.97 0.85–1.12 0.97 0.84–1.11
55Smi415 55 213 1.04 0.77–1.40 0.99 0.73–1.34
Smi 47 140 1.35 0.97–1.88 1.16 0.81–1.66
P (trend) 0.05 0.36
Other 3199 12 740 1.16 0.92–1.45 1.14 0.90–1.44
11–15 years 0 1774 7162 1.00 Referrent 1.00 Referrent
05Smi45 210 901 0.94 0.80–1.11 0.94 0.80–1.10
55Smi415 39 139 1.13 0.79–1.62 1.11 0.77–1.60
Smi415 39 73 2.14 1.45–3.17 2.02 1.34–3.04
P (trend) 0.002 0.01
Other 3820 15 242 1.07 0.88–1.31 1.05 0.86–1.29
aSee Subjects and Methods.
bRRs were calculated with conditional logistic regression because of matching for age and index date but were not
adjusted for the effects of exposure during the other periods.
cRRs were calculated with conditional logistic regression because of matching for
age and index date and were adjusted for the effects of exposure during the other periods.
dRRs for this category for these periods were not
estimated because of insufﬁcient variation: since cases and controls were matched for index date, if exposure was missing for a case, due to the
1.5 year gap in the exposure histories beginning July 1, 1987, it was always missing for the matched controls, so they were all classiﬁed as ‘other’
and contributed no information to the matched analysis.
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obtained information about antidepressant use for only the 2 weeks
period preceding inception of the cohort. Although they considered
the possibility that antidepressant drug use may have increased the
risk of cancer and controlled for it, it is unlikely that they
controlled adequately for antidepressant drug use with such limited
information. Furthermore, they did not consider that some antide-
pressants might be more hazardous than others. Similarly, Gallo et
al (2000) obtained information on depression status at baseline and
cancer at follow-up 13 years later for 2017 persons. They found no
overall association between depression and the development of
cancer. Among women, however, there was an association between
major depression and breast cancer. The RR adjusted for age,
tobacco use, and alcohol abuse was 3.8 (95% CI: 1.0–14.3); this
estimate was based on 25 breast cancer cases. They reported that
adjustment ‘for use of psychotropic medicines and use of health-
care services at baseline’ did not change this estimate substantially.
No further details of this adjustment were provided, nor were they
able to study the interval between major depression and the diag-
nosis of cancer.
Nevertheless, if other determinants of breast cancer (Sharpe
and Boivin, 2000) were associated with TCA use, it is possible
that our results might be attributable to confounding by such
determinants. It is unlikely, however, that strong positive
confounding associated with the use of the genotoxic TCAs led
to an apparent effect stronger than the overall effect of TCA
exposure (compare the right panels of Tables 3 and 4 to the
right panel of Table 2), while strong negative confounding asso-
ciated with the use of the nongenotoxic TCAs led to an apparent
lack of effect. TCAs are usually prescribed for depression without
consideration of subtle details of their chemical structures and
without consideration of breast cancer as an adverse effect. Expo-
sure to the genotoxic TCAs may have increased the risk of breast
cancer, while exposure to the nongenotoxic TCAs may have had
no effect on risk.
Since selection bias, recall bias, exposure misclassiﬁcation, and
chance are unlikely explanations for our ﬁndings, and differential
patterns of confounding according to the chemical structures of
the drugs seem unlikely, a biologic explanation may be required.
The 410 year delay between exposure to the genotoxic TCAs
and the increase in the RR for breast cancer is suggestive of tumour
initiation rather than tumour promotion. Ionizing radiation, the
prototypical initiator, increases the risk of breast cancer after a
delay of 10 years (Land, 1987).
The results of TCA genotoxicity assays involving bacteria, Droso-
phila, and human lymphocytes are conﬂicting (van Schaik and
Graf, 1991). The consistency between the results of the assays
carried out by van Schaik and Graf (1991, 1993) and Graf
(2001) in Drosophila and our epidemiologic ﬁndings suggests that
it may be the most appropriate.
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Table 3 RRs for breast cancer according to TCA exposure by time period before diagnosis. Subjects may have been treated
with TCAs from either of the two categories, or with TCAs from both
Nongenotoxic TCAs
a Genotoxic TCAs
b
Period before
diagnosis
Average daily dose
(moles610
75 day
71)
Cases
n=5882
Controls
n=23517 RR
c 95% CI
Cases
n=5882
Controls
n=23517 RR
c 95% CI
1–6 months 0 4926 19 721 1.00 Referrent
d 4918 19 755 1.00 Referrent
e
05Smi45 66 233 1.12 0.84–1.51 64 200 1.24 0.91–1.68
55Smi415 56 244 0.99 0.69–1.42 56 219 0.88 0.61–1.27
Smi415 51 189 0.94 0.55–1.59 61 213 0.76 0.48–1.20
P (trend) 0.36 0.49
Other 783 3130 – – 783 3130 – –
7–12 months 0 4902 19 609 1.00 Referrent
d 4890 19 647 1.00 Referrent
e
05Smi45 62 218 1.12 0.82–1.52 54 203 1.05 0.76–1.46
55Smi415 51 254 0.79 0.54–1.16 57 208 1.10 0.76–1.60
Smi415 55 191 1.08 0.64–1.84 69 214 1.44 0.91–2.29
P (trend) 0.65 0.25
Other 812 3245 – – 812 3245 – –
2–5 years 0 3057 12 207 1.00 Referrent
d 3039 12 134 1.00 Referrent
e
05Smi45 185 769 0.97 0.82–1.15 181 816 0.86 0.73–1.03
55Smi415 39 165 0.97 0.66–1.42 56 155 1.31 0.94–1.83
Smi415 26 84 1.20 0.72–1.99 31 120 0.86 0.55–1.36
P (trend) 0.62 0.80
Other 2575 10 292 – – 2575 10 292 – –
6–10 years 0 2459 9876 1.00 Referrent
d 2429 9816 1.00 Referrent
e
05Smi45 175 743 0.93 0.78–1.11 194 755 1.03 0.87–1.22
55Smi415 33 109 1.18 0.79–1.78 33 129 0.91 0.61–1.36
Smi415 16 49 1.25 0.69–2.27 27 77 1.15 0.72–1.84
P (trend) 0.31 0.68
Other 3199 12 740 1.14 0.90–1.44 3199 12 740 1.14 0.90–1.44
11–15 years 0 1898 7662 1.00 Referrent
d 1863 7584 1.00 Referrent
e
05Smi45 136 503 1.03 0.84–1.26 146 592 1.00 0.83–1.22
05Smi415 17 72 0.82 0.47–1.41 32 66 1.93 1.25–2.99
Smi415 11 38 0.99 0.49–1.99 21 33 2.47 1.37–4.40
P (trend) 0.58 0.0009
Other 3820 15 242 1.06 0.87–1.30 3820 15 242 1.06 0.87–1.30
aAmitriptyline, maprotiline, nortriptyline, protriptyline.
bAmoxapine, clomipramine, desipramine, doxepin, imipramine, trimipramine.
cRRs were
calculated with conditional logistic regression because of matching for age and index date and adjusted for the effects of exposure during the
other periods. The variables representing exposure to the nongenotoxic TCAs and to the genotoxic TCAs were all included in a single logistic
model.
dUnexposed to nongenotoxic TCAs during that period.
eUnexposed to genotoxic TCAs during that period.
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ciations between TCA use and the development of cancer
(Danielson et al, 1982; Friedman and Ury, 1980, 1983; Kelly et
al, 1999; Selby et al, 1989; Weiss et al, 1998), they were limited
either by small sample size, self-reporting of use, failure to specify
dosage, duration of use, or timing of use, and lack of control of
confounding. Recently, Wang et al (2001) followed 38273 women
who ﬁlled a prescription for an antidepressant over a period of up
to 24 months, and 32949 women who ﬁlled a prescription for any
other medication over the same period. Both groups were followed
for a maximum of 7.5 years. TCA use was not associated with the
development of breast cancer (RR=1.09; 95% CI: 0.92–1.31),
which is consistent with our ﬁnding that TCA use was not asso-
ciated with any increase in risk with until at least 10 years had
elapsed.
Two other studies have reported positive associations between
TCA use and the development of breast cancer. Wallace et al
(1982) carried out a case–control study of antidepressant use
(TCAs or phenelzine) in relation to breast cancer incidence and
obtained an adjusted RR=2.8 (P50.04) for use 41 month. In a
similar study, Cotterchio et al (2000) found that TCA use for
525 months was associated with an adjusted RR=2.1 (95% CI:
0.9–5.0). Neither study speciﬁed dosage or the timing of use.
Another two studies reported positive associations between anti-
depressant use and the development of other cancers. Harlow and
Cramer (1995) carried out a case–control study of ovarian cancer
incidence and obtained an adjusted RR=2.1 (95% CI: 0.9–4.8) for
any prior use of antidepressants or benzodiazepines lasting 56
months. Among women who ﬁrst used these drugs before age 50
years the RR was 3.5 (95% CI: 1.3–9.2). Among those who used
them 510 years before diagnosis, the RR was 9.7 (95% CI: 1.2–
78.8). These ﬁndings, however, were not corroborated by Coogan
et al (2000). Both studies were based on self-reported exposures.
Dalton et al (2000) conducted a population-based cohort study
in Denmark using the nation’s prescription database. They
followed 30807 antidepressant users aged 515 years for up to 7
years (mean=3.2 years) and found an increased risk of non-Hodg-
kin’s lymphoma among subjects who received 55 prescriptions for
TCAs (standardized incidence ratio=2.5; 95% CI: 1.4–4.2).
CONCLUSION
Taken together, our results and those of others suggest that the
relations between TCA use and the development of breast cancer
and other cancers as well should be evaluated further in studies
designed speciﬁcally to test the hypothesis that the TCAs found
to be genotoxic by van Schaik and Graf (1991, 1993) and Graf
(personal communication), are carcinogenic, in which potential
confounding by other determinants can be controlled.
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Table 4 RRs for breast cancer according to estimated duration of TCA use by time period before diagnosis. Subjects may
have been treated with TCAs from either of the two categories, or with TCAs from both
Nongenotoxic TCAs
a Genotoxic TCAs
b
Period before diagnosis
Duration
of use
Cases
n=5882
Controls
n=23517 RR
c 95% CI
Cases
n=5882
Controls
n=23517 RR
c 95% CI
0–1 year 0 4670 18 702 1.00 Referrent
d 4666 18 766 1.00 Referrent
e
1%–40% 77 287 1.07 0.83–1.38 69 260 1.07 0.81–1.40
41%–70% 35 138 1.00 0.68–1.46 40 107 1.48 1.02–2.15
71%–100% 102 401 0.99 0.77–1.28 109 395 0.94 0.73–1.22
P (trend) 0.95 0.74
Other 998 3989 – – 998 3989 – –
2–5 years 0 3061 12 223 1.00 Referrent
d 3042 12 167 1.00 Referrent
e
1%–40% 187 769 0.97 0.81–1.15 186 825 0.88 0.74–1.05
41%–70% 16 83 0.78 0.45–1.35 27 79 1.34 0.85–2.12
71%–100% 41 142 1.13 0.76–1.67 50 146 1.28 0.88–1.84
P (trend) 0.96 0.55
Other 2577 10 300 – – 2577 10 300 – –
6–10 years 0 2461 9889 1.00 Referrent
d 2428 9822 1.00 Referrent
e
1%–40% 183 754 0.95 0.80–1.14 208 804 1.03 0.87–1.22
41%–70% 21 67 1.20 0.73–1.99 24 72 1.20 0.75–1.93
71%–100% 20 72 1.10 0.66–1.83 25 84 1.02 0.64–1.62
P (trend) 0.86 0.60
Other 3197 12 735 1.14 0.90–1.44 3197 12 735 1.14 0.90–1.44
11–15 years 0 1914 7707 1.00 Referrent
d 1874 7636 1.00 Referrent
e
1%–40% 138 533 0.97 0.79–1.19 155 611 1.04 0.86–1.26
41%–70% 8 38 0.74 0.34–1.61 27 54 1.99 1.23–3.20
71%–100% 14 53 1.02 0.56–1.86 18 30 2.39 1.30–4.39
P (trend) 0.71 0.003
Other 3808 15 186 1.08 0.88–1.32 3808 15 186 1.08 0.88–1.32
aAmitriptyline, maprotiline, nortriptyline, protriptyline.
bAmoxapine, clomipramine, desipramine, doxepin, imipramine, trimipramine.
cRRs were
calculated with conditional logistic regression because of matching for age and index date and adjusted for the effects of exposure during the
other periods. The variables representing exposure to the nongenotoxic TCAs and to the genotoxic TCAs were all included in a single logistic
model.
dUnexposed to nongenotoxic TCAs during that period. The numbers of unexposed subjects during each time period differ slightly from
the values for the corresponding periods in Table 3 because the lengths of the periods differ slightly.
eUnexposed to genotoxic TCAs during that
period. The numbers of unexposed subjects during each time period differ slightly from the values for the corresponding periods in Table 3
because the lengths of the periods differ slightly.
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The study was based in part on data provided by the Saskatchewan
Department of Health. The interpretation and conclusions
contained in this report do not necessarily represent those of the
Government of Saskatchewan or the Saskatchewan Department of
Health. The study was also based on data provided by the
Saskatchewan Cancer Agency, which bears no responsibility for
the analysis of the data or the interpretation of the results.
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